Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.78 |
| ▸ | BRD2 | P25440 | 2/20 | 0.78 |
| ▸ | SMCHD1 | A6NHR9 | 1/20 | 0.78 |
| ▸ | MYO1G | B0I1T2 | 1/20 | 0.78 |
| ▸ | AIP | O00170 | 1/20 | 0.78 |
| ▸ | AP3B1 | O00203 | 1/20 | 0.78 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.78 |
| ▸ | CDC7 | O00311 | 1/20 | 0.78 |
| ▸ | SAP18 | O00422 | 1/20 | 0.78 |
| ▸ | KPNA3 | O00505 | 1/20 | 0.78 |
| ▸ | PPP6C | O00743 | 1/20 | 0.78 |
| ▸ | TCERG1 | O14776 | 1/20 | 0.78 |
| ▸ | UBE2L6 | O14933 | 1/20 | 0.78 |
| ▸ | PPP1R12A | O14974 | 1/20 | 0.78 |
| ▸ | U2SURP | O15042 | 1/20 | 0.78 |
| ▸ | SETD1A | O15047 | 1/20 | 0.78 |
| ▸ | ARPC1B | O15143 | 1/20 | 0.78 |
| ▸ | POLR1C | O15160 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380378 | 1.00 | BRD4 (0.78) | BRD4HDAC1HDAC2BRD2SMCHD1 | |
| SCHEMBL15981812 | 0.93 | BRD4 (0.79) | BRD4HDAC1HDAC2BRD2SMCHD1 | |
| SCHEMBL1869987 | 0.93 | BRD4 (0.79) | BRD4HDAC1HDAC2BRD2SMCHD1 | |
| SCHEMBL29377393 | 0.93 | BRD4 (0.79) | BRD4HDAC1HDAC2BRD2SMCHD1 | |
| SCHEMBL25215661 | 0.92 | BRD4 (0.85) | BRD4HDAC1HDAC2BRD2SMCHD1 | |
| SCHEMBL14756861 | 0.92 | BRD4 (0.81) | BRD4HDAC1HDAC2BRD2SMCHD1 | |
| SCHEMBL29377764 | 0.92 | BRD4 (0.81) | BRD4HDAC1HDAC2BRD2SMCHD1 | |
| SCHEMBL15968213 | 0.91 | BRD4 (0.73) | BRD4HDAC1HDAC2BRD2SMCHD1 | |
| SCHEMBL15981852 | 0.91 | BRD4 (0.78) | BRD4HDAC1HDAC2BRD2SMCHD1 | |
| SCHEMBL15967894 | 0.91 | BRD4 (0.70) | BRD4HDAC1HDAC2BRD2SMCHD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| EP-4192825-A2 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192504-A2 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000950-A1 | THERAPEUTIC CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USING THEM | BET1, BRD4, BAZ2A | BRD4 2/4885HDAC1 107/4885HDAC2 507/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | BRD4 331/4885HDAC1 957/4885HDAC2 2749/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | BRD4 2/4885HDAC1 158/4885HDAC2 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.